Skip to main content
SpringerLink
Log in

Hidradenitis Suppurativa

  • Chapter
  • First Online:
Severe Skin Diseases in Children

  • 1173 Accesses

Abstract

Hidradenitis suppurativa (HS, acne inversa) is a chronic and recurrent disease affecting the apocrine-bearing areas of skin. Although previously thought to arise from inflammation of the apocrine glands, evidence now points to follicular occlusion as the primary event, though the disease has distinct differences from acne vulgaris where occlusion also plays a role. Hidradenitis suppurativa varies in severity, ranging from occasional isolated inflammatory nodules to numerous painful inflammatory nodules with draining ulcers, sinus tracts, and scarring. While there is no cure for hidradenitis suppurativa, nor a standard protocol for treatment, therapy can help control the disease. Treatment options including oral antibiotics, hormonal therapy, immunosuppressants, biologics, and surgery are reviewed. In addition to medical and surgical therapy, supporting the psychosocial well-being of HS patients, especially adolescents, is very important, and HS support groups or referral for psychological evaluation can be helpful.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

FDA:

Food and Drug Administration

HS:

Hidradenitis suppurativa

Kg:

Kilogram

Mg:

Milligram

Nd:YAG:

Neodymium:yttrium-aluminum-garnet

PUVA:

Psoralen plus ultraviolet A

References

  1. Mengesha YM, Holcombe TC, Hansen RC. Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Pediatr Dermatol. 1999;16(4):292–6.

    Article  PubMed  CAS  Google Scholar 

  2. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother. 2004;5:1767–70.

    Article  PubMed  CAS  Google Scholar 

  3. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case–control studies. J Am Acad Dermatol. 2008;59:596–601.

    Article  PubMed  Google Scholar 

  4. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitits suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.

    Article  PubMed  CAS  Google Scholar 

  5. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.

    Google Scholar 

  6. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa – characteristics and consequences. Clin Exp Dermatol. 1996;21:419–23.

    Article  PubMed  CAS  Google Scholar 

  7. Von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809–13.

    Article  PubMed  Google Scholar 

  8. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328–32.

    Article  PubMed  Google Scholar 

  9. Clemmensen OJ. Topical treatment of hidradenitits suppurativa with clindamycin. Int J Dermatol. 1983;22:325–8.

    Article  PubMed  CAS  Google Scholar 

  10. Jemec GB, Faber M, Gutschik E, et al. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193:203–6.

    Article  PubMed  CAS  Google Scholar 

  11. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140:90–5.

    Article  PubMed  CAS  Google Scholar 

  12. Sartorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166:879–83.

    Article  PubMed  CAS  Google Scholar 

  13. Shaughnessy DM, Greminger RR, Margolis IB, et al. Hidradenitis suppurativa. A plea for early operative treatment. JAMA. 1972;222:320–1.

    Article  PubMed  CAS  Google Scholar 

  14. Jemec GB, Wendelbow P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–4.

    Article  PubMed  CAS  Google Scholar 

  15. Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977–8.

    Article  PubMed  Google Scholar 

  16. Van der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–7.

    Article  PubMed  Google Scholar 

  17. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148–54.

    Article  PubMed  CAS  Google Scholar 

  18. Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49–58.

    Article  PubMed  CAS  Google Scholar 

  19. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–3.

    Article  PubMed  CAS  Google Scholar 

  20. Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342–6.

    Article  PubMed  CAS  Google Scholar 

  21. Jones DH, Cunliffe WJ, King K. Hidradenitis suppurativa—lack of success with 13-cis-retinoic acid. Br J Dermatol. 1982;107:252.

    Google Scholar 

  22. Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984;11:500–2.

    Article  PubMed  CAS  Google Scholar 

  23. Norris JFB, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11:579–83.

    Article  PubMed  CAS  Google Scholar 

  24. Brown CF, Gallup DG, Brown VM. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988;158:12–5.

    Article  PubMed  CAS  Google Scholar 

  25. Boer J, van Gemert M. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73–6.

    Article  PubMed  CAS  Google Scholar 

  26. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218:134–5.

    Article  PubMed  CAS  Google Scholar 

  27. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5.

    Article  PubMed  CAS  Google Scholar 

  28. Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre-and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134:1057–9.

    Article  PubMed  CAS  Google Scholar 

  29. Joseph MA, Jayaseelan E, Ganapathi B, et al. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat. 2005;16:75–8.

    Article  PubMed  CAS  Google Scholar 

  30. Mortimer PS, Dawber RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–8.

    Article  PubMed  CAS  Google Scholar 

  31. Sawers RS, Randall VA, Ebline FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269–74.

    Article  PubMed  CAS  Google Scholar 

  32. Roase RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral cyclosporine. Clin Exp Dermatol. 2006;31:154–6.

    Article  Google Scholar 

  33. Buckley DA, Rogers S. Cyclosprin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289P–90.

    PubMed  CAS  Google Scholar 

  34. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:523–9.

    Google Scholar 

  35. Van der Zee HH, Prens EP. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology. 2011;223:169–73.

    Article  PubMed  Google Scholar 

  36. Van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–8.

    Article  PubMed  Google Scholar 

  37. Adams DR, Gordon KB, Devenyi AG, et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540–2.

    Article  PubMed  Google Scholar 

  38. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–9.

    PubMed  CAS  Google Scholar 

  39. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046–9.

    Article  PubMed  CAS  Google Scholar 

  40. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343–5.

    Article  PubMed  Google Scholar 

  41. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46: 1287–91.

    Article  PubMed  Google Scholar 

  42. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41–4.

    Article  PubMed  CAS  Google Scholar 

  43. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;154:1105–7.

    Article  Google Scholar 

  44. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumor necrosis factor-α blockers the ultimate alternative? Br J Dermatol. 2008;159:761–3.

    Article  PubMed  CAS  Google Scholar 

  45. Lasocki A, Sinclair R, Foley P, et al. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51:186–90.

    Article  PubMed  Google Scholar 

  46. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–4.

    Article  PubMed  CAS  Google Scholar 

  47. Delage M, Samimi M, Atlan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol. 2011;91:169–71.

    PubMed  Google Scholar 

  48. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624–8.

    Article  PubMed  Google Scholar 

  49. Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204–5.

    Article  PubMed  CAS  Google Scholar 

  50. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17.

    Article  PubMed  CAS  Google Scholar 

  51. Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol. 2009;89:82–3.

    PubMed  CAS  Google Scholar 

  52. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–72.

    Article  PubMed  CAS  Google Scholar 

  53. Pelekanou A, Kanni T, Savva A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol. 2010;19:538–40.

    Article  PubMed  CAS  Google Scholar 

  54. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60:565–73.

    Article  PubMed  Google Scholar 

  55. Zangrilli A, Esposito M, Mio G, et al. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2008;22:1260–2.

    Article  PubMed  CAS  Google Scholar 

  56. Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.

    Article  PubMed  CAS  Google Scholar 

  57. Moul DK, Korman N. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110–1.

    Article  PubMed  Google Scholar 

  58. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580–4.

    Article  PubMed  Google Scholar 

  59. Sotiriou E, Apalla Z, Vakirilis E, et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19:180–1.

    PubMed  Google Scholar 

  60. Amando M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49: 950–5.

    Article  Google Scholar 

  61. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49:1445–9.

    Article  PubMed  Google Scholar 

  62. Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(Suppl):15–20.

    Google Scholar 

  63. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–8.

    Article  PubMed  CAS  Google Scholar 

  64. Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911–4.

    Article  PubMed  CAS  Google Scholar 

  65. Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320–1.

    Article  PubMed  CAS  Google Scholar 

  66. Bong JL, Shalders K, Saihan E. Treatment of persistent painful nodules of hidradenitis suppurativa with cryotherapy. Clin Exp Dermatol. 2003;28:241–4.

    Article  PubMed  CAS  Google Scholar 

  67. Guglielmetti A, Bedoya J, Acuna M, et al. Successful aminolevulinic acid photodynamic therapy for recalcitrant severe hidradenitis suppurativa. Photodermatol Photoimmunol Photomed. 2010;26:110–1.

    Article  PubMed  Google Scholar 

  68. Saraceno R, Teoli M, Casciello C, et al. Methyl aminolaevulinate photodynamic therapy for the treatment of hidradenitis suppurativa and pilonidal cysts. Photodermatol Photoimmunol Photomed. 2009;25: 164–5.

    Article  PubMed  CAS  Google Scholar 

  69. Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol. 2011;10:381–6.

    PubMed  CAS  Google Scholar 

  70. Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol. 2004;3:S32–5.

    PubMed  Google Scholar 

  71. Sotiriou E, Apalla Z, Maliamani F, et al. Treatment of recalcitrant hidradenitis suppurativa with photodynamic therapy: report of five cases. Clin Exp Dermatol. 2009;34:e235–6.

    Article  PubMed  CAS  Google Scholar 

  72. Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol. 2005;152:803–4.

    Article  PubMed  CAS  Google Scholar 

  73. Shareef M, Dawe R. Bath psoralen plus ultraviolet A for hidradenitis suppurativa: a review of 13 patients. Br J Dermatol. 2011;164:895–6.

    Article  PubMed  CAS  Google Scholar 

  74. O’Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116:1575–6.

    Article  PubMed  Google Scholar 

  75. Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol. 1994;131:551–6.

    Article  PubMed  CAS  Google Scholar 

  76. Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996;34:465–9.

    Article  PubMed  CAS  Google Scholar 

  77. Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002;47:280–5.

    Article  PubMed  Google Scholar 

  78. Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36:208–13.

    Article  PubMed  CAS  Google Scholar 

  79. Madan V, Hindle E, Hussain W, et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008;159:1309–14.

    Article  PubMed  CAS  Google Scholar 

  80. Mahmoud BH, Tierney E, Hexsel C, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62:637–45.

    Article  PubMed  Google Scholar 

  81. Ritz JP, Runkel N, Haier J, et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13:164–8.

    Article  PubMed  CAS  Google Scholar 

  82. Van Hattem S, Spoo JR, Horvath B, et al. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012;38:494–7.

    Article  PubMed  Google Scholar 

  83. Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475–80.

    Article  PubMed  Google Scholar 

  84. Bohn J, Svensson H. Surgical treatment of hidradenitis suppurativa. Scand J Plast Reconstr Surg Hand Surg. 2001;35:305–9.

    Article  PubMed  CAS  Google Scholar 

  85. Bieniek A, Matusiak L, Okulewicz-Gojlik D, et al. Surgical treatment of hidradenitis suppurativa: experiences and recommendations. Dermatol Surg. 2010;36:1998–2004.

    Article  PubMed  CAS  Google Scholar 

  86. Buyukasik O, Hasdemir AO, Kahramansoy N, et al. Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg. 2011;37:835–42.

    Article  PubMed  CAS  Google Scholar 

  87. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26:638–43.

    Article  PubMed  CAS  Google Scholar 

  88. Watson JD. Hidradenitis suppurativa – a clinical review. Br J Plast Surg. 1985;38:567–9.

    Article  PubMed  CAS  Google Scholar 

  89. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. Surgeon. 2005;3:23–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology and General Pediatrics, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, 3550 Market Street, 2nd Floor, Philadelphia, PA, 19146, USA

    Melinda Jen MD

  2. Dermatology and Pediatrics, University of Connecticut School of Medicine, 65 Memorial Road, Suite 450, West Hartford, CT, 06107, USA

    Mary Wu Chang MD

Authors
  1. Melinda Jen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Wu Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melinda Jen MD .

Editor information

Editors and Affiliations

  1. Pediatric & Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA

    Wynnis L. Tom

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jen, M., Chang, M.W. (2014). Hidradenitis Suppurativa. In: Tom, W. (eds) Severe Skin Diseases in Children. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39532-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39532-1_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39531-4

  • Online ISBN: 978-3-642-39532-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation